STOCK TITAN
  1. Home
  2. News
  3. OBIO

Orchestra BioMed Holdings, Inc. Ordinary Shares - OBIO STOCK NEWS

Welcome to our dedicated page for Orchestra BioMed Holdings Ordinary Shares news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings Ordinary Shares stock.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company dedicated to bringing high-impact technologies to patients through strategic partnerships. The company's unique business model relies on risk-reward sharing collaborations with leading medical device companies, facilitating global commercialization of its innovative products.

Core Offerings and Innovations

  • BackBeat Cardiac Neuromodulation Therapy (CNT): This flagship product targets hypertension, an extensive global health issue. BackBeat CNT uses atrioventricular interval modulation (AVIM) therapy administered through standard dual-chamber pacemakers to significantly and persistently reduce blood pressure.
  • Virtue Sirolimus AngioInfusion Balloon (SAB): This product is aimed at treating atherosclerotic artery disease, the leading cause of mortality worldwide. The Virtue SAB is a novel drug-delivery system designed to address the specific needs of patients with this condition.

Recent Achievements

In January 2024, Orchestra BioMed announced the successful randomization of the first patient in the BACKBEAT pivotal study, aimed at assessing the efficacy and safety of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension. This study is crucial for determining the effectiveness of the BackBeat CNT in reducing blood pressure.

Strategic Partnerships

Orchestra BioMed has formed pivotal partnerships to drive its mission. In July 2022, the company entered a strategic collaboration with Medtronic for the commercialization of AVIM therapy. This partnership will enable Medtronic to exclusively commercialize AVIM-enabled pacing systems globally, with Orchestra BioMed sharing in the resultant revenues. Additionally, a strategic partnership with Terumo focuses on the development and commercialization of Virtue SAB.

Financial Condition and Market Presence

Orchestra BioMed is financially robust and strategically positioned in the biomedical sector, with a clear focus on growing its product pipeline through acquisitions, strategic collaborations, and organic development. This approach ensures sustained innovation and market relevance.

For more detailed information, visit www.orchestrabiomed.com and follow the company on LinkedIn and X (formerly Twitter).

News

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Rhea-AI Summary
Orchestra BioMed appoints David Pacitti, President of Siemens Medical Solutions USA, to its Board of Directors. Mr. Pacitti brings extensive experience in cardiovascular devices and strategic partnerships, enhancing the company's leadership and connections in the medical device industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.2%
Tags
management
-
News

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

Rhea-AI Summary
Orchestra BioMed announces positive pharmacokinetic data on Virtue SAB and favorable clinical results on AVIM therapy at CRT 2024 Meeting. Virtue SAB enables extended release of sirolimus without polymer degradation, while AVIM therapy shows long-term blood pressure reduction. The Company is collaborating with Medtronic for the BACKBEAT global pivotal study.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.37%
Tags
none
-
News

Orchestra BioMed to Participate in Upcoming Investor Conferences

Rhea-AI Summary
Orchestra BioMed Holdings, Inc. (OBIO) announced their participation in upcoming conferences in March 2024 to present high-impact technologies through risk-reward sharing partnerships. The company will be presenting at the Oppenheimer Annual Healthcare MedTech and Services Conference on March 12, 2024, and at the Barclays 26th Annual Global Healthcare Conference on March 14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.62%
Tags
conferences
News

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Rhea-AI Summary
Orchestra BioMed announces positive clinical data on AVIM therapy for hypertensive pacemaker patients, showing significant reductions in blood pressure and favorable hemodynamic effects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
clinical trial
-
News

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

Rhea-AI Summary
Orchestra BioMed announces significant long-term blood pressure reduction with AVIM therapy in hypertensive pacemaker patients. The MODERATO II study shows an 8.9 mmHg mean reduction in 24-hour ambulatory systolic blood pressure over 3.6 years. AVIM therapy aims to reduce blood pressure using a pacemaker. Orchestra BioMed collaborates with Medtronic for commercialization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
News

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Rhea-AI Summary
Orchestra BioMed Holdings, Inc. (OBIO) and Medtronic, Inc. (MDT) have announced an exclusive strategic collaboration for the development and commercialization of AVIM therapy for hypertensive pacemaker population, with the first patient randomized in the BACKBEAT pivotal study. The study aims to evaluate the efficacy and safety of AVIM therapy for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. The study is a global, multi-center, prospective, randomized, double-blind study investigating the efficacy and safety of AVIM therapy in patients who have recently undergone implantation of a Medtronic dual-chamber cardiac pacemaker and have uncontrolled hypertension despite the use of antihypertensive medications. The primary efficacy endpoint will determine at three months post-randomization whether AVIM-treated patients experience a statistically significant reduction in daily average blood pressure (mean 24-hour ambulatory systolic blood pressure or “aSBP”) as compared to control patients. The primary safety endpoint will determine at three months post-randomization whether AVIM-treated patients experience serious adverse device effects that are not anticipated with cardiac pacing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.38%
Tags
none
News

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Orchestra BioMed (OBIO) announced FDA approval for pivotal studies of BackBeat CNT therapy in hypertensive pacemaker patients and Virtue SAB in coronary ISR patients. The company's third-quarter financial results revealed a cash runway until 2H 2026, with revenue and net loss details.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.08%
Tags
earnings
-
News

Orchestra BioMed to Present at Upcoming Investor Conferences

Rhea-AI Summary
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that company management will present at multiple healthcare conferences in November and December, including the Jefferies London Healthcare Conference and the Piper Sandler Healthcare Conference. The presentations will be available via webcast on the company's Investor Relations section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.35%
Tags
conferences
-
News

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Rhea-AI Summary
Orchestra BioMed receives FDA approval for BACKBEAT study on AVIM therapy for hypertensive pacemaker patients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
27.61%
Tags
fda approval
News

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
earnings

FAQ

What is the current stock price of Orchestra BioMed Holdings Ordinary Shares (OBIO)?

The current stock price of Orchestra BioMed Holdings Ordinary Shares (OBIO) is $5.84 as of November 15, 2024.

What is the market cap of Orchestra BioMed Holdings Ordinary Shares (OBIO)?

The market cap of Orchestra BioMed Holdings Ordinary Shares (OBIO) is approximately 231.1M.

What does Orchestra BioMed Holdings, Inc. specialize in?

Orchestra BioMed Holdings specializes in accelerating high-impact biomedical technologies to patients through strategic risk-reward sharing partnerships with leading medical device companies.

What are the flagship products of Orchestra BioMed?

The flagship products include BackBeat Cardiac Neuromodulation Therapy (CNT) for hypertension and Virtue Sirolimus AngioInfusion Balloon (SAB) for atherosclerotic artery disease.

What recent milestone has Orchestra BioMed achieved?

In January 2024, Orchestra BioMed announced the randomization of the first patient in the BACKBEAT pivotal study, aimed at evaluating the efficacy and safety of AVIM therapy.

Who are Orchestra BioMed's strategic partners?

Orchestra BioMed has strategic partnerships with Medtronic for AVIM therapy and Terumo for Virtue SAB.

What is BackBeat CNT?

BackBeat CNT (Cardiac Neuromodulation Therapy) is a therapy that uses atrioventricular interval modulation (AVIM) to significantly lower blood pressure in patients with hypertension.

What is Virtue Sirolimus AngioInfusion Balloon (SAB)?

Virtue SAB is an innovative drug-delivery system designed to treat atherosclerotic artery disease, the leading cause of mortality worldwide.

How does Orchestra BioMed's business model work?

Orchestra BioMed's business model focuses on risk-reward sharing partnerships with leading medical device companies to accelerate the commercialization of its innovative technologies.

Where can I find more information about Orchestra BioMed?

You can visit the company's website at www.orchestrabiomed.com and follow them on LinkedIn and X (formerly Twitter).

What is the focus of the BACKBEAT pivotal study?

The BACKBEAT pivotal study focuses on evaluating the efficacy and safety of AVIM therapy in patients with high blood pressure who also need pacemakers.

What is hypertension and why is it significant?

Hypertension, or high blood pressure, is a condition that increases the force of blood against blood vessels, leading to higher risks of major cardiac events like heart attacks and strokes.

Stock OBIO logo
Orchestra BioMed Holdings, Inc. Ordinary Shares

Nasdaq:OBIO

OBIO Rankings

#3741 Ranked by Market Cap
N/A Ranked by Dividends

OBIO Stock Data

231.11M
38.01M
22.59%
53.17%
2.18%
Biotechnology
Surgical & Medical Instruments & Apparatus
Link
United States of America
NEW HOPE